Sean Khozin - Concepedia

Author

Sean Khozin

United States Food and Drug Administration ORCID

Also Known As

Khozin, Sean, S Khozin, S. Khozin, Sean Khozin, Shahram Khozin, Yentram Huyen

Publications

5.2K

Citations

H-Index

Concepts

All Affiliations

United States Food and Drug Administration Flatiron Health (United States)National Cancer Institute Dana-Farber Cancer Institute Center for Drug Evaluation and Research

About

Sean Khozin is an author at United States Food and Drug Administration specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	9	9	988
2	Education	2	2	189
3	Engineering	2	2	110
4	Management	2	2	209
5	Business	1	1	115

Sean Khozin

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Real-world Data for Clinical Evidence Generation in Oncology Sean Khozin, Gideon M. Blumenthal, Richard Pazdur JNCI Journal of the National Cancer Institute Clinical EndpointReal-world EvidenceCancer RegistrationOncologyClinical Trials	2017	332
Developing and adopting safe and effective digital biomarkers to improve patient outcomes Andrea Coravos, Sean Khozin, Kenneth D. Mandl npj Digital Medicine	2019	314
FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer Sean Khozin, Gideon M. Blumenthal, Lijun Zhang, Clinical Cancer Research PathologyFda ApprovalPharmacotherapyPre-clinical PharmacologyMeaningful Orr	2015	182
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer Ronan J. Kelly, Anish Thomas, Arun Rajan, Annals of Oncology Phase I/ii StudyMedicinePharmacologyBronchial NeoplasmSurvivin Suppressor	2013	171
Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer Gideon M. Blumenthal, Yuexuan Gong, Kenneth L. Kehl, Annals of Oncology Time-to-treatment DiscontinuationMedicineClinical TrialsBronchial NeoplasmImmune Checkpoint Inhibitor	2019	151
Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer Sandra D. Griffith, Melisa Tucker, Bryan Bowser, Advances in Therapy	2019	151
U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations Sean Khozin, Gideon M. Blumenthal, Xiaoping Jiang, The Oncologist Preclinical TherapeuticsCancer ManagementMetastatic NsclcPathologyFirst-line Treatment	2014	140
U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non–Small Cell Lung Cancer Chana Weinstock, Sean Khozin, Daniel L. Suzman, Clinical Cancer Research	2017	135
Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer Sean Khozin, Rebecca A. Miksad, Johan Adami, Cancer	2019	135
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer Mark Stewart, Andrew D. Norden, Nancy A Dreyer, JCO Clinical Cancer Informatics	2019	129

Page 1